Overview

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

Status:
Recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of ascending doses of the MEK-inhibitor zapnometinib (ATR-002) given as single doses (SAD Part) and as multiple doses for 7 days (MAD Part) in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Atriva Therapeutics GmbH

Treatments:

Celecoxib
Repaglinide